Search Results - Jeremy M. Shefner
- Showing 1 - 20 results of 48
- Go to Next Page
-
1
-
2
-
3
Lead Exposure and Amyotrophic Lateral Sclerosis by Freya Kamel, David M. Umbach, Theodore L. Munsat, Jeremy M. Shefner, Howard Hu, Dale P. Sandler
Published 2002Artigo -
4
-
5
-
6
-
7
Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis by Jinsy Andrews, Lisa Meng, Sarah Kulke, Stacy A. Rudnicki, Andrew A. Wolff, Michael Bozik, Fady I. Malik, Jeremy M. Shefner
Published 2017Artigo -
8
-
9
Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system by Jeremy M. Shefner, Seward B. Rutkove, James B. Caress, Michael Benatar, William S. David, Michael S. Cartwright, Eric A. Macklin, Jose L. Bohorquez
Published 2018Artigo -
10
-
11
Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice by Michael Benatar, Lyle W. Ostrow, Joseph W. Lewcock, Frank Bennett, Jeremy M. Shefner, Robert Bowser, Paul Larkin, Lucie Bruijn, Joanne Wuu
Published 2023Revisão -
12
-
13
Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self‐report scale (Center for Neurologic Study Bulbar Function Scale) by Richard Smith, Eric A. Macklin, Kathleen Myers, Gary L. Pattee, Kimberly Goslin, Gregg Meekins, J. R. Green, Jeremy M. Shefner, Erik P. Pioro
Published 2018Artigo -
14
Repeatability of Commonly Used Speech and Language Features for Clinical Applications by Gabriela Stegmann, Shira Hahn, Julie Liss, Jeremy M. Shefner, Seward B. Rutkove, Kan Kawabata, Samarth Bhandari, Kerisa Shelton, Cayla Jessica Duncan, Visar Berisha
Published 2020Artigo -
15
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial by Swati Aggarwal, Lorne Zinman, Elizabeth Simpson, Jane McKinley, Katherine E. Jackson, Hanika Pinto, Petra Kaufman, Robin Conwit, David Schoenfeld, Jeremy M. Shefner, Merit Cudkowicz
Published 2010Artigo -
16
-
17
-
18
A phase III trial of <i>tirasemtiv</i> as a potential treatment for amyotrophic lateral sclerosis by Jeremy M. Shefner, Merit Cudkowicz, Orla Hardiman, Bettina M. Cockroft, Jacqueline H. Lee, Fady I. Malik, Lisa Meng, Stacy A. Rudnicki, Andrew A. Wolff, Jinsy Andrews
Published 2019Artigo -
19
-
20
Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking by Shinji Hadano, Susanna C. Benn, Shigeru Kakuta, Asako Otomo, Katsuko Sudo, Ryota Kunita, Kyoko Suzuki-Utsunomiya, Hikaru Mizumura, Jeremy M. Shefner, Gregory A. Cox, Yoichiro Iwakura, Robert H. Brown, Joh‐E Ikeda
Published 2005Artigo
Search Tools:
Related Subjects
Medicine
Disease
Internal medicine
Amyotrophic lateral sclerosis
Pathology
Clinical trial
Physical therapy
Alternative medicine
Placebo
Biology
Physical medicine and rehabilitation
Psychology
Randomized controlled trial
Clinical endpoint
Neuroscience
Adverse effect
Mathematics
Gene
Genetics
Paleontology
Pharmacology
Rating scale
Statistics
Tolerability
Anesthesia
Bioinformatics
Biomarker
Computer science
Dementia
Developmental psychology